A comparative clinical study of S-1108 and cefteram pivoxil in chronic respiratory tract infections by a double-blind method

Atsushi Saito; Hiroshi Fukuhara; Jun Inadome; Yoshikazu Kawakami; Etsuro Yamaguchi; Akira Saito; Ichiro Nakayama; Masumi Tomizawa; Yohmei Hiraga; Mitsuhide Ohmichi; Masashi Tamura; Kazuki Konishi; Kazuo Obara; Kunio Shirato; Yasuo Tanno; Akira Watanabe; Kiyoshi Konno; Tsuneo Sayama; Satoru Shoji; Mitsunobu Honma; Hiroyuki Nakai; Yoshihiro Honda; Masataka Katsu; Michihiro Sakauti; Akira Ohishi; Atsushi Saito; Kohya Shiba; Osamu Sakai; Hiroichi Tanimoto; Kaoru Shimada; Yasuyuki Sano; Yasufumi Miyamoto; Hiroyuki Kobayashi; Shin Kawai; Susumu Sakayori; Izumi Hayashi; Koichiro Kudo; Tadashi Horiuchi; Takashi Inamatsu; Masaru Koyama; Takeshi Mori; Koichiro Nakata; Tatsuo Nakatani; Harumi Shishido; Hideaki Nagai; Otohiko Kunii; Yoshio Uzuka; Jingoro Shimada; Seiji Hori; Takao Okubo; Hirotada Ikeda; Hiroo Yamakawa; Fumio Matsumoto; Takeo Imai; Shigeki Odagiri; Kaneo Suzuki; Hiroshi Takahashi; Ken ichi Takahashi; Takashi Ogura; Eri Hagiwara; Masaaki Arakawa; Koichi Wada; Fumihide Iwata; Nobuki Aoki; Osamu Sekine; Yasutoshi Suzuki; Kaoru Shimokata; Toshiyuki Yamamoto; Kanzo Suzuki; Toru Matuura; Shigeru Shirakawa; Shin ichi Kageyama; Kojiro Yasunaga; Seibun Yonezu; Yoshitaka Yamanaka; Fumio Miki; Masaru Nakagawa; Nobuhiro Narita; Masayoshi Sawaki; Keiichi Mikasa; Rinzo Soejima; Yoshihito Niki; Niro Okimoto; Michio Yamakido; Soichiro Hozawa; Hideto Yamakido; Takao Sasaki; Yukio Matsumoto; Yuji Sugimoto; Minoru Yoshida; Masayuki Nakanishi; Kotaro Oizumi; Yoichiro Ichikawa; Naoto Tokunaga; Tohru Rikimaru; Atsushi Shinoda; Tsuneo Ishibashi; Masahiro Takamoto; Hozumi Yamada; Osamu Katoh; Masaru Nasu; Tohru Yamasaki; Yoichiro Goto; Kohei Hara; Shigeru Konno; Hitonobu Koga; Mitsuo Kaku; Keizo Matsumoto; Tsuyoshi Nagatake; Yoshiaki Utsunomiya; Mitsuyoshi Nakashima; Intetsu Kobayashi

doi:10.11250/chemotherapy1953.42.476

A comparative clinical study of S-1108 and cefteram pivoxil in chronic respiratory tract infections by a double-blind method

Atsushi Saito, Hiroshi Fukuhara, Jun Inadome, Yoshikazu Kawakami, Etsuro Yamaguchi, Akira Saito, Ichiro Nakayama, Masumi Tomizawa, Yohmei Hiraga, Mitsuhide Ohmichi, Masashi Tamura, Kazuki Konishi, Kazuo Obara, Kunio Shirato, Yasuo Tanno, Akira Watanabe, Kiyoshi Konno, Tsuneo Sayama, Satoru Shoji, Mitsunobu HonmaHiroyuki Nakai, Yoshihiro Honda, Masataka Katsu, Michihiro Sakauti, Akira Ohishi, Atsushi Saito, Kohya Shiba, Osamu Sakai, Hiroichi Tanimoto, Kaoru Shimada, Yasuyuki Sano, Yasufumi Miyamoto, Hiroyuki Kobayashi, Shin Kawai, Susumu Sakayori, Izumi Hayashi, Koichiro Kudo, Tadashi Horiuchi, Takashi Inamatsu, Masaru Koyama, Takeshi Mori, Koichiro Nakata, Tatsuo Nakatani, Harumi Shishido, Hideaki Nagai, Otohiko Kunii, Yoshio Uzuka, Jingoro Shimada, Seiji Hori, Takao Okubo, Hirotada Ikeda, Hiroo Yamakawa, Fumio Matsumoto, Takeo Imai, Shigeki Odagiri, Kaneo Suzuki, Hiroshi Takahashi, Ken ichi Takahashi, Takashi Ogura, Eri Hagiwara, Masaaki Arakawa, Koichi Wada, Fumihide Iwata, Nobuki Aoki, Osamu Sekine, Yasutoshi Suzuki, Kaoru Shimokata, Toshiyuki Yamamoto, Kanzo Suzuki, Toru Matuura, Shigeru Shirakawa, Shin ichi Kageyama, Kojiro Yasunaga, Seibun Yonezu, Yoshitaka Yamanaka, Fumio Miki, Masaru Nakagawa, Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Rinzo Soejima, Yoshihito Niki, Niro Okimoto, Michio Yamakido, Soichiro Hozawa, Hideto Yamakido, Takao Sasaki, Yukio Matsumoto, Yuji Sugimoto, Minoru Yoshida, Masayuki Nakanishi, Kotaro Oizumi, Yoichiro Ichikawa, Naoto Tokunaga, Tohru Rikimaru, Atsushi Shinoda, Tsuneo Ishibashi, Masahiro Takamoto, Hozumi Yamada, Osamu Katoh, Masaru Nasu, Tohru Yamasaki, Yoichiro Goto, Kohei Hara, Shigeru Konno, Hitonobu Koga, Mitsuo Kaku, Keizo Matsumoto, Tsuyoshi Nagatake, Yoshiaki Utsunomiya, Mitsuyoshi Nakashima, Intetsu Kobayashi

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

We conducted a comparative double-blind study of S-1108, a new ester-type oral cephem antibiotic, and cefteram pivoxil (CFTM-PI) to evaluate the efficacy, safety and usefulness of these drugs in the treatment of chronic respiratory tract infections excluding diffuse panbroncholitis. S-1108 was given orally at a daily dose of 450 mg, and CFTM-PI at a daily dose of 600 mg three times daily for 14 days. The following results were obtained. 1) Of the total 171 patients (86 in the S-1108 group, 85 in the CFTM-PI group), 157 patients (81 in the S-1108 group, 76 in the CFTM-PI group) were evaluated for efficacy. No significant difference was noted between the two drug groups with respect to the percent excluded or background factors of patients. 2) The clinical efficacy rate were 80.2%(65/81 patients) in the S-1108 group, and 78.9%(60/76 patients) in the CFTM-PI group, showing no significant differences between the two groups. 3) Bacteriologically, the elimination rates of causative organisms were 60.5%(23/38 patients) in the S-1108 group and 65.9%(27/41 patients) in the CFTM-PI group, with no significant differences. 4) Side effects were observed in 6.9%(5/83) of patients in the S-1108 group and 6.4%(5/78) of patients in the CFTM-PI group. Abnormal changes in laboratory findings were observed in 13.9%(11/79) of patients in the S-1108 group and 13.9%(10/72) of patients in the CFTM-PI group. There were no significant differences in incidence between the two groups. None of the side effects were severe. 5) The utility rates (very satisfactory and satisfactory) were 77.1%(64/83 patients) in the S-1108 group and 77.6%(59/76 patients) in the CFTM-PI group, with no significant differences between the two groups. The above results indicate that S-1108 at a daily dose of 450 mg is as useful as CFTM-PI at a daily dose of 600 mg in the treatment of chronic respiratory tract infections.

Original language	English
Pages (from-to)	476-503
Number of pages	28
Journal	Chemotherapy
Volume	42
Issue number	4
DOIs	https://doi.org/10.11250/chemotherapy1953.42.476
Publication status	Published - 1994
Externally published	Yes

Keywords

S-1108
cefteram pivoxil
chronic respiratory infection
double blind study

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.42.476

Cite this

Saito, A., Fukuhara, H., Inadome, J., Kawakami, Y., Yamaguchi, E., Saito, A., Nakayama, I., Tomizawa, M., Hiraga, Y., Ohmichi, M., Tamura, M., Konishi, K., Obara, K., Shirato, K., Tanno, Y., Watanabe, A., Konno, K., Sayama, T., Shoji, S., ... Kobayashi, I. (1994). A comparative clinical study of S-1108 and cefteram pivoxil in chronic respiratory tract infections by a double-blind method. Chemotherapy, 42(4), 476-503. https://doi.org/10.11250/chemotherapy1953.42.476

A comparative clinical study of S-1108 and cefteram pivoxil in chronic respiratory tract infections by a double-blind method. / Saito, Atsushi; Fukuhara, Hiroshi; Inadome, Jun; Kawakami, Yoshikazu; Yamaguchi, Etsuro; Saito, Akira; Nakayama, Ichiro; Tomizawa, Masumi; Hiraga, Yohmei; Ohmichi, Mitsuhide; Tamura, Masashi; Konishi, Kazuki; Obara, Kazuo; Shirato, Kunio; Tanno, Yasuo; Watanabe, Akira; Konno, Kiyoshi; Sayama, Tsuneo; Shoji, Satoru; Honma, Mitsunobu; Nakai, Hiroyuki; Honda, Yoshihiro; Katsu, Masataka; Sakauti, Michihiro; Ohishi, Akira; Saito, Atsushi; Shiba, Kohya; Sakai, Osamu; Tanimoto, Hiroichi; Shimada, Kaoru; Sano, Yasuyuki; Miyamoto, Yasufumi; Kobayashi, Hiroyuki; Kawai, Shin; Sakayori, Susumu; Hayashi, Izumi; Kudo, Koichiro; Horiuchi, Tadashi; Inamatsu, Takashi; Koyama, Masaru; Mori, Takeshi; Nakata, Koichiro; Nakatani, Tatsuo; Shishido, Harumi; Nagai, Hideaki; Kunii, Otohiko; Uzuka, Yoshio; Shimada, Jingoro; Hori, Seiji; Okubo, Takao; Ikeda, Hirotada; Yamakawa, Hiroo; Matsumoto, Fumio; Imai, Takeo; Odagiri, Shigeki; Suzuki, Kaneo; Takahashi, Hiroshi; Takahashi, Ken ichi; Ogura, Takashi; Hagiwara, Eri; Arakawa, Masaaki; Wada, Koichi; Iwata, Fumihide; Aoki, Nobuki; Sekine, Osamu; Suzuki, Yasutoshi; Shimokata, Kaoru; Yamamoto, Toshiyuki; Suzuki, Kanzo; Matuura, Toru; Shirakawa, Shigeru; Kageyama, Shin ichi; Yasunaga, Kojiro; Yonezu, Seibun; Yamanaka, Yoshitaka; Miki, Fumio; Nakagawa, Masaru; Narita, Nobuhiro; Sawaki, Masayoshi; Mikasa, Keiichi; Soejima, Rinzo; Niki, Yoshihito; Okimoto, Niro; Yamakido, Michio; Hozawa, Soichiro; Yamakido, Hideto; Sasaki, Takao; Matsumoto, Yukio; Sugimoto, Yuji; Yoshida, Minoru; Nakanishi, Masayuki; Oizumi, Kotaro; Ichikawa, Yoichiro; Tokunaga, Naoto; Rikimaru, Tohru; Shinoda, Atsushi; Ishibashi, Tsuneo; Takamoto, Masahiro; Yamada, Hozumi; Katoh, Osamu; Nasu, Masaru; Yamasaki, Tohru; Goto, Yoichiro; Hara, Kohei; Konno, Shigeru; Koga, Hitonobu; Kaku, Mitsuo; Matsumoto, Keizo; Nagatake, Tsuyoshi; Utsunomiya, Yoshiaki; Nakashima, Mitsuyoshi; Kobayashi, Intetsu.

In: Chemotherapy, Vol. 42, No. 4, 1994, p. 476-503.

Research output: Contribution to journal › Article › peer-review

Saito, A, Fukuhara, H, Inadome, J, Kawakami, Y, Yamaguchi, E, Saito, A, Nakayama, I, Tomizawa, M, Hiraga, Y, Ohmichi, M, Tamura, M, Konishi, K, Obara, K, Shirato, K, Tanno, Y, Watanabe, A, Konno, K, Sayama, T, Shoji, S, Honma, M, Nakai, H, Honda, Y, Katsu, M, Sakauti, M, Ohishi, A, Saito, A, Shiba, K, Sakai, O, Tanimoto, H, Shimada, K, Sano, Y, Miyamoto, Y, Kobayashi, H, Kawai, S, Sakayori, S, Hayashi, I, Kudo, K, Horiuchi, T, Inamatsu, T, Koyama, M, Mori, T, Nakata, K, Nakatani, T, Shishido, H, Nagai, H, Kunii, O, Uzuka, Y, Shimada, J, Hori, S, Okubo, T, Ikeda, H, Yamakawa, H, Matsumoto, F, Imai, T, Odagiri, S, Suzuki, K, Takahashi, H, Takahashi, KI, Ogura, T, Hagiwara, E, Arakawa, M, Wada, K, Iwata, F, Aoki, N, Sekine, O, Suzuki, Y, Shimokata, K, Yamamoto, T, Suzuki, K, Matuura, T, Shirakawa, S, Kageyama, SI, Yasunaga, K, Yonezu, S, Yamanaka, Y, Miki, F, Nakagawa, M, Narita, N, Sawaki, M, Mikasa, K, Soejima, R, Niki, Y, Okimoto, N, Yamakido, M, Hozawa, S, Yamakido, H, Sasaki, T, Matsumoto, Y, Sugimoto, Y, Yoshida, M, Nakanishi, M, Oizumi, K, Ichikawa, Y, Tokunaga, N, Rikimaru, T, Shinoda, A, Ishibashi, T, Takamoto, M, Yamada, H, Katoh, O, Nasu, M, Yamasaki, T, Goto, Y, Hara, K, Konno, S, Koga, H, Kaku, M, Matsumoto, K, Nagatake, T, Utsunomiya, Y, Nakashima, M & Kobayashi, I 1994, 'A comparative clinical study of S-1108 and cefteram pivoxil in chronic respiratory tract infections by a double-blind method', Chemotherapy, vol. 42, no. 4, pp. 476-503. https://doi.org/10.11250/chemotherapy1953.42.476

Saito, Atsushi ; Fukuhara, Hiroshi ; Inadome, Jun ; Kawakami, Yoshikazu ; Yamaguchi, Etsuro ; Saito, Akira ; Nakayama, Ichiro ; Tomizawa, Masumi ; Hiraga, Yohmei ; Ohmichi, Mitsuhide ; Tamura, Masashi ; Konishi, Kazuki ; Obara, Kazuo ; Shirato, Kunio ; Tanno, Yasuo ; Watanabe, Akira ; Konno, Kiyoshi ; Sayama, Tsuneo ; Shoji, Satoru ; Honma, Mitsunobu ; Nakai, Hiroyuki ; Honda, Yoshihiro ; Katsu, Masataka ; Sakauti, Michihiro ; Ohishi, Akira ; Saito, Atsushi ; Shiba, Kohya ; Sakai, Osamu ; Tanimoto, Hiroichi ; Shimada, Kaoru ; Sano, Yasuyuki ; Miyamoto, Yasufumi ; Kobayashi, Hiroyuki ; Kawai, Shin ; Sakayori, Susumu ; Hayashi, Izumi ; Kudo, Koichiro ; Horiuchi, Tadashi ; Inamatsu, Takashi ; Koyama, Masaru ; Mori, Takeshi ; Nakata, Koichiro ; Nakatani, Tatsuo ; Shishido, Harumi ; Nagai, Hideaki ; Kunii, Otohiko ; Uzuka, Yoshio ; Shimada, Jingoro ; Hori, Seiji ; Okubo, Takao ; Ikeda, Hirotada ; Yamakawa, Hiroo ; Matsumoto, Fumio ; Imai, Takeo ; Odagiri, Shigeki ; Suzuki, Kaneo ; Takahashi, Hiroshi ; Takahashi, Ken ichi ; Ogura, Takashi ; Hagiwara, Eri ; Arakawa, Masaaki ; Wada, Koichi ; Iwata, Fumihide ; Aoki, Nobuki ; Sekine, Osamu ; Suzuki, Yasutoshi ; Shimokata, Kaoru ; Yamamoto, Toshiyuki ; Suzuki, Kanzo ; Matuura, Toru ; Shirakawa, Shigeru ; Kageyama, Shin ichi ; Yasunaga, Kojiro ; Yonezu, Seibun ; Yamanaka, Yoshitaka ; Miki, Fumio ; Nakagawa, Masaru ; Narita, Nobuhiro ; Sawaki, Masayoshi ; Mikasa, Keiichi ; Soejima, Rinzo ; Niki, Yoshihito ; Okimoto, Niro ; Yamakido, Michio ; Hozawa, Soichiro ; Yamakido, Hideto ; Sasaki, Takao ; Matsumoto, Yukio ; Sugimoto, Yuji ; Yoshida, Minoru ; Nakanishi, Masayuki ; Oizumi, Kotaro ; Ichikawa, Yoichiro ; Tokunaga, Naoto ; Rikimaru, Tohru ; Shinoda, Atsushi ; Ishibashi, Tsuneo ; Takamoto, Masahiro ; Yamada, Hozumi ; Katoh, Osamu ; Nasu, Masaru ; Yamasaki, Tohru ; Goto, Yoichiro ; Hara, Kohei ; Konno, Shigeru ; Koga, Hitonobu ; Kaku, Mitsuo ; Matsumoto, Keizo ; Nagatake, Tsuyoshi ; Utsunomiya, Yoshiaki ; Nakashima, Mitsuyoshi ; Kobayashi, Intetsu. / A comparative clinical study of S-1108 and cefteram pivoxil in chronic respiratory tract infections by a double-blind method. In: Chemotherapy. 1994 ; Vol. 42, No. 4. pp. 476-503.

@article{861c2f2cab7d4c1f98b8b588e052f173,

title = "A comparative clinical study of S-1108 and cefteram pivoxil in chronic respiratory tract infections by a double-blind method",

abstract = "We conducted a comparative double-blind study of S-1108, a new ester-type oral cephem antibiotic, and cefteram pivoxil (CFTM-PI) to evaluate the efficacy, safety and usefulness of these drugs in the treatment of chronic respiratory tract infections excluding diffuse panbroncholitis. S-1108 was given orally at a daily dose of 450 mg, and CFTM-PI at a daily dose of 600 mg three times daily for 14 days. The following results were obtained. 1) Of the total 171 patients (86 in the S-1108 group, 85 in the CFTM-PI group), 157 patients (81 in the S-1108 group, 76 in the CFTM-PI group) were evaluated for efficacy. No significant difference was noted between the two drug groups with respect to the percent excluded or background factors of patients. 2) The clinical efficacy rate were 80.2%(65/81 patients) in the S-1108 group, and 78.9%(60/76 patients) in the CFTM-PI group, showing no significant differences between the two groups. 3) Bacteriologically, the elimination rates of causative organisms were 60.5%(23/38 patients) in the S-1108 group and 65.9%(27/41 patients) in the CFTM-PI group, with no significant differences. 4) Side effects were observed in 6.9%(5/83) of patients in the S-1108 group and 6.4%(5/78) of patients in the CFTM-PI group. Abnormal changes in laboratory findings were observed in 13.9%(11/79) of patients in the S-1108 group and 13.9%(10/72) of patients in the CFTM-PI group. There were no significant differences in incidence between the two groups. None of the side effects were severe. 5) The utility rates (very satisfactory and satisfactory) were 77.1%(64/83 patients) in the S-1108 group and 77.6%(59/76 patients) in the CFTM-PI group, with no significant differences between the two groups. The above results indicate that S-1108 at a daily dose of 450 mg is as useful as CFTM-PI at a daily dose of 600 mg in the treatment of chronic respiratory tract infections.",

keywords = "S-1108, cefteram pivoxil, chronic respiratory infection, double blind study",

author = "Atsushi Saito and Hiroshi Fukuhara and Jun Inadome and Yoshikazu Kawakami and Etsuro Yamaguchi and Akira Saito and Ichiro Nakayama and Masumi Tomizawa and Yohmei Hiraga and Mitsuhide Ohmichi and Masashi Tamura and Kazuki Konishi and Kazuo Obara and Kunio Shirato and Yasuo Tanno and Akira Watanabe and Kiyoshi Konno and Tsuneo Sayama and Satoru Shoji and Mitsunobu Honma and Hiroyuki Nakai and Yoshihiro Honda and Masataka Katsu and Michihiro Sakauti and Akira Ohishi and Atsushi Saito and Kohya Shiba and Osamu Sakai and Hiroichi Tanimoto and Kaoru Shimada and Yasuyuki Sano and Yasufumi Miyamoto and Hiroyuki Kobayashi and Shin Kawai and Susumu Sakayori and Izumi Hayashi and Koichiro Kudo and Tadashi Horiuchi and Takashi Inamatsu and Masaru Koyama and Takeshi Mori and Koichiro Nakata and Tatsuo Nakatani and Harumi Shishido and Hideaki Nagai and Otohiko Kunii and Yoshio Uzuka and Jingoro Shimada and Seiji Hori and Takao Okubo and Hirotada Ikeda and Hiroo Yamakawa and Fumio Matsumoto and Takeo Imai and Shigeki Odagiri and Kaneo Suzuki and Hiroshi Takahashi and Takahashi, {Ken ichi} and Takashi Ogura and Eri Hagiwara and Masaaki Arakawa and Koichi Wada and Fumihide Iwata and Nobuki Aoki and Osamu Sekine and Yasutoshi Suzuki and Kaoru Shimokata and Toshiyuki Yamamoto and Kanzo Suzuki and Toru Matuura and Shigeru Shirakawa and Kageyama, {Shin ichi} and Kojiro Yasunaga and Seibun Yonezu and Yoshitaka Yamanaka and Fumio Miki and Masaru Nakagawa and Nobuhiro Narita and Masayoshi Sawaki and Keiichi Mikasa and Rinzo Soejima and Yoshihito Niki and Niro Okimoto and Michio Yamakido and Soichiro Hozawa and Hideto Yamakido and Takao Sasaki and Yukio Matsumoto and Yuji Sugimoto and Minoru Yoshida and Masayuki Nakanishi and Kotaro Oizumi and Yoichiro Ichikawa and Naoto Tokunaga and Tohru Rikimaru and Atsushi Shinoda and Tsuneo Ishibashi and Masahiro Takamoto and Hozumi Yamada and Osamu Katoh and Masaru Nasu and Tohru Yamasaki and Yoichiro Goto and Kohei Hara and Shigeru Konno and Hitonobu Koga and Mitsuo Kaku and Keizo Matsumoto and Tsuyoshi Nagatake and Yoshiaki Utsunomiya and Mitsuyoshi Nakashima and Intetsu Kobayashi",

year = "1994",

doi = "10.11250/chemotherapy1953.42.476",

language = "English",

volume = "42",

pages = "476--503",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

number = "4",

}

TY - JOUR

T1 - A comparative clinical study of S-1108 and cefteram pivoxil in chronic respiratory tract infections by a double-blind method

AU - Saito, Atsushi

AU - Fukuhara, Hiroshi

AU - Inadome, Jun

AU - Kawakami, Yoshikazu

AU - Yamaguchi, Etsuro

AU - Saito, Akira

AU - Nakayama, Ichiro

AU - Tomizawa, Masumi

AU - Hiraga, Yohmei

AU - Ohmichi, Mitsuhide

AU - Tamura, Masashi

AU - Konishi, Kazuki

AU - Obara, Kazuo

AU - Shirato, Kunio

AU - Tanno, Yasuo

AU - Watanabe, Akira

AU - Konno, Kiyoshi

AU - Sayama, Tsuneo

AU - Shoji, Satoru

AU - Honma, Mitsunobu

AU - Nakai, Hiroyuki

AU - Honda, Yoshihiro

AU - Katsu, Masataka

AU - Sakauti, Michihiro

AU - Ohishi, Akira

AU - Saito, Atsushi

AU - Shiba, Kohya

AU - Sakai, Osamu

AU - Tanimoto, Hiroichi

AU - Shimada, Kaoru

AU - Sano, Yasuyuki

AU - Miyamoto, Yasufumi

AU - Kobayashi, Hiroyuki

AU - Kawai, Shin

AU - Sakayori, Susumu

AU - Hayashi, Izumi

AU - Kudo, Koichiro

AU - Horiuchi, Tadashi

AU - Inamatsu, Takashi

AU - Koyama, Masaru

AU - Mori, Takeshi

AU - Nakata, Koichiro

AU - Nakatani, Tatsuo

AU - Shishido, Harumi

AU - Nagai, Hideaki

AU - Kunii, Otohiko

AU - Uzuka, Yoshio

AU - Shimada, Jingoro

AU - Hori, Seiji

AU - Okubo, Takao

AU - Ikeda, Hirotada

AU - Yamakawa, Hiroo

AU - Matsumoto, Fumio

AU - Imai, Takeo

AU - Odagiri, Shigeki

AU - Suzuki, Kaneo

AU - Takahashi, Hiroshi

AU - Takahashi, Ken ichi

AU - Ogura, Takashi

AU - Hagiwara, Eri

AU - Arakawa, Masaaki

AU - Wada, Koichi

AU - Iwata, Fumihide

AU - Aoki, Nobuki

AU - Sekine, Osamu

AU - Suzuki, Yasutoshi

AU - Shimokata, Kaoru

AU - Yamamoto, Toshiyuki

AU - Suzuki, Kanzo

AU - Matuura, Toru

AU - Shirakawa, Shigeru

AU - Kageyama, Shin ichi

AU - Yasunaga, Kojiro

AU - Yonezu, Seibun

AU - Yamanaka, Yoshitaka

AU - Miki, Fumio

AU - Nakagawa, Masaru

AU - Narita, Nobuhiro

AU - Sawaki, Masayoshi

AU - Mikasa, Keiichi

AU - Soejima, Rinzo

AU - Niki, Yoshihito

AU - Okimoto, Niro

AU - Yamakido, Michio

AU - Hozawa, Soichiro

AU - Yamakido, Hideto

AU - Sasaki, Takao

AU - Matsumoto, Yukio

AU - Sugimoto, Yuji

AU - Yoshida, Minoru

AU - Nakanishi, Masayuki

AU - Oizumi, Kotaro

AU - Ichikawa, Yoichiro

AU - Tokunaga, Naoto

AU - Rikimaru, Tohru

AU - Shinoda, Atsushi

AU - Ishibashi, Tsuneo

AU - Takamoto, Masahiro

AU - Yamada, Hozumi

AU - Katoh, Osamu

AU - Nasu, Masaru

AU - Yamasaki, Tohru

AU - Goto, Yoichiro

AU - Hara, Kohei

AU - Konno, Shigeru

AU - Koga, Hitonobu

AU - Kaku, Mitsuo

AU - Matsumoto, Keizo

AU - Nagatake, Tsuyoshi

AU - Utsunomiya, Yoshiaki

AU - Nakashima, Mitsuyoshi

AU - Kobayashi, Intetsu

PY - 1994

Y1 - 1994

N2 - We conducted a comparative double-blind study of S-1108, a new ester-type oral cephem antibiotic, and cefteram pivoxil (CFTM-PI) to evaluate the efficacy, safety and usefulness of these drugs in the treatment of chronic respiratory tract infections excluding diffuse panbroncholitis. S-1108 was given orally at a daily dose of 450 mg, and CFTM-PI at a daily dose of 600 mg three times daily for 14 days. The following results were obtained. 1) Of the total 171 patients (86 in the S-1108 group, 85 in the CFTM-PI group), 157 patients (81 in the S-1108 group, 76 in the CFTM-PI group) were evaluated for efficacy. No significant difference was noted between the two drug groups with respect to the percent excluded or background factors of patients. 2) The clinical efficacy rate were 80.2%(65/81 patients) in the S-1108 group, and 78.9%(60/76 patients) in the CFTM-PI group, showing no significant differences between the two groups. 3) Bacteriologically, the elimination rates of causative organisms were 60.5%(23/38 patients) in the S-1108 group and 65.9%(27/41 patients) in the CFTM-PI group, with no significant differences. 4) Side effects were observed in 6.9%(5/83) of patients in the S-1108 group and 6.4%(5/78) of patients in the CFTM-PI group. Abnormal changes in laboratory findings were observed in 13.9%(11/79) of patients in the S-1108 group and 13.9%(10/72) of patients in the CFTM-PI group. There were no significant differences in incidence between the two groups. None of the side effects were severe. 5) The utility rates (very satisfactory and satisfactory) were 77.1%(64/83 patients) in the S-1108 group and 77.6%(59/76 patients) in the CFTM-PI group, with no significant differences between the two groups. The above results indicate that S-1108 at a daily dose of 450 mg is as useful as CFTM-PI at a daily dose of 600 mg in the treatment of chronic respiratory tract infections.

AB - We conducted a comparative double-blind study of S-1108, a new ester-type oral cephem antibiotic, and cefteram pivoxil (CFTM-PI) to evaluate the efficacy, safety and usefulness of these drugs in the treatment of chronic respiratory tract infections excluding diffuse panbroncholitis. S-1108 was given orally at a daily dose of 450 mg, and CFTM-PI at a daily dose of 600 mg three times daily for 14 days. The following results were obtained. 1) Of the total 171 patients (86 in the S-1108 group, 85 in the CFTM-PI group), 157 patients (81 in the S-1108 group, 76 in the CFTM-PI group) were evaluated for efficacy. No significant difference was noted between the two drug groups with respect to the percent excluded or background factors of patients. 2) The clinical efficacy rate were 80.2%(65/81 patients) in the S-1108 group, and 78.9%(60/76 patients) in the CFTM-PI group, showing no significant differences between the two groups. 3) Bacteriologically, the elimination rates of causative organisms were 60.5%(23/38 patients) in the S-1108 group and 65.9%(27/41 patients) in the CFTM-PI group, with no significant differences. 4) Side effects were observed in 6.9%(5/83) of patients in the S-1108 group and 6.4%(5/78) of patients in the CFTM-PI group. Abnormal changes in laboratory findings were observed in 13.9%(11/79) of patients in the S-1108 group and 13.9%(10/72) of patients in the CFTM-PI group. There were no significant differences in incidence between the two groups. None of the side effects were severe. 5) The utility rates (very satisfactory and satisfactory) were 77.1%(64/83 patients) in the S-1108 group and 77.6%(59/76 patients) in the CFTM-PI group, with no significant differences between the two groups. The above results indicate that S-1108 at a daily dose of 450 mg is as useful as CFTM-PI at a daily dose of 600 mg in the treatment of chronic respiratory tract infections.

KW - S-1108

KW - cefteram pivoxil

KW - chronic respiratory infection

KW - double blind study

UR - http://www.scopus.com/inward/record.url?scp=0028292229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028292229&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.42.476

DO - 10.11250/chemotherapy1953.42.476

M3 - Article

AN - SCOPUS:0028292229

VL - 42

SP - 476

EP - 503

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

IS - 4

ER -

A comparative clinical study of S-1108 and cefteram pivoxil in chronic respiratory tract infections by a double-blind method

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this